Protein degrader specialist Lycia prices $318M IPO
Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.